<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602393</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1014-PR-0053 POLEP</org_study_id>
    <secondary_id>2010-024270-19</secondary_id>
    <nct_id>NCT01602393</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety &amp; Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase</brief_title>
  <acronym>CT04 POLEP</acronym>
  <official_title>A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of ascending oral doses
      of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine maximum tolerated dose of CHF 5074 after multiple oral once daily administration to patients with mild cognitive impairment</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>CHF 5074 1x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5074 2x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 5074 3x</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral tablet, multidose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074 1x</intervention_name>
    <description>oral tablet, 1x, once a day in the morning for 48 weeks</description>
    <arm_group_label>CHF 5074 1x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074 2x</intervention_name>
    <description>oral tablet, 2x, once a day in the morning for 48 weeks</description>
    <arm_group_label>CHF 5074 2x</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5074 3x</intervention_name>
    <description>oral tablet, 3x, once a day in the morning for 48 weeks</description>
    <arm_group_label>CHF 5074 3x</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of amnestic or non-amnestic Mild Cognitive Impairment.

          -  Mini-Mental State Examination score higher than 24 at screening.

          -  MRI scan of the brain at screening with fluid-attenuation inversion recovery (FLAIR)
             and T2*-weighted gradient-recalled-echo (GRE) sequences.

        Exclusion Criteria:

          -  Diagnosis of Alzheimer's disease according to the (DSM-IV-TR) or NINCDS-ADRDA
             criteria.

          -  Any medical condition that could explain the patients cognitive deficits.

          -  CT or MRI brain imaging results obtained within 12 months prior to baseline showing
             evidence of infection, infarction, or focal lesions of clinical significance

          -  MRI scan at screening showing more than 4 cerebral microhemorrhages (lesions with
             diameter â‰¤ 10 mm).

          -  Geriatric Depression Scale (30-point scale) score &gt; 9 at screening.

          -  History of stroke.

          -  Modified Hachinski ischemic scale score &gt; 4 at screening.

          -  Women of childbearing potential.

          -  Vitamin B12 or folate deficiency.

          -  Diagnosis of schizophrenia or recurrent mood disorder (including unipolar and bipolar
             disorders) within 3 years of screening.

          -  Current diagnosis of peptic ulcer or gastrointestinal bleeding within the last year
             and/or chronic inflammatory bowel disease.

          -  Concomitant use of donepezil at doses &gt; 5 mg/day or other cholinesterase inhibitors
             (rivastigmine or galantamine) at any dose.

          -  Concomitant use of memantine at dose &gt; 20 mg/day.

          -  Concomitant use of psychoactive drugs (sedatives, hypnotics, etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel S Ross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memory Enhancement Center of America, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriella Bottini, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osp. Niguarda Ca Granda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memory Enhancement Center of America, Inc.</name>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <zip>07724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Center of New Jersey, Inc.</name>
      <address>
        <city>Monroe Twp</city>
        <state>New Jersey</state>
        <zip>08831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memory Enhancement Center of NJ, Inc.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Niguarda Ca'Granda, Dip. Di Neuroscienze</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <disposition_first_submitted>January 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 6, 2014</disposition_first_posted>
  <last_update_submitted>January 7, 2014</last_update_submitted>
  <last_update_submitted_qc>January 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 5, 2015</submitted>
    <returned>December 10, 2015</returned>
    <submitted>February 4, 2016</submitted>
    <returned>March 2, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

